Recursion Pharmaceuticals, Inc. (RXRX)

NASDAQ: RXRX · IEX Real-Time Price · USD

8.79

+0.45 (5.40%)

At close: May 2, 2024, 4:00 PM

8.81

+0.02 (0.23%)

After-hours: May 2, 2024, 7:55 PM EDT

Recursion Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Net Income	-328.07	-239.48	-186.48	-87.01	-61.88
Depreciation & Amortization	32.47	19.49	8.41	3.94	2.49
Share-Based Compensation	53.5	27.91	14.84	4.29	1.39
Other Operating Activities	-45.68	108.56	4.62	33.37	0.96
Operating Cash Flow	-287.78	-83.52	-158.61	-45.4	-57.04
Capital Expenditures	-11.96	-37.06	-39.8	-5.83	-3.91
Acquisitions	1.84	0	0	-2.6	0
Change in Investments	0.48	230.61	-231.95	0.6	0
Other Investing Activities	-0.6	-0.3	-	-0.9	-
Investing Cash Flow	-10.23	193.25	-271.74	-8.74	-3.91
Share Issuance / Repurchase	140.9	154.44	471.34	0.68	0.07
Debt Issued / Paid	-0.77	-0.09	-12.8	6.32	0.43
Other Financing Activities	-	-	-	239.13	119.92
Financing Cash Flow	140.13	154.35	458.54	246.14	120.41
Exchange Rate Effect	0.19	-0.31	0	0	0
Net Cash Flow	-157.69	263.76	28.18	192	59.46
Free Cash Flow	-299.74	-120.58	-198.41	-51.23	-60.95
Free Cash Flow Margin	-672.43%	-302.65%	-1949.42%	-1293.03%	-2628.37%
Free Cash Flow Per Share	-1.44	-0.69	-1.58	-2.35	-2.83

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).